ongoing clinical trials of ruxolitinib-based combinations in myelofibrosis
Published 2 years ago • 132 plays • Length 5:12Download video MP4
Download video MP3
Similar videos
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
2:10
phase i study of ruxolitinib in combination with abemaciclib in patients with myelofibrosis
-
1:15
ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis
-
2:39
a phase ii trial of ruxolitinib and azacitidine combination therapy in patients with myelofibrosis
-
1:18
novel approaches for the treatment of myelofibrosis: navitoclax ruxolitinib
-
1:30
results of the ruxopeg trial: combining ruxolitinib and interferon in patients with myelofibrosis
-
10:54
jakafi (ruxolitinib) the new medication of polycythemia vera and myelofibrosis. mechanism of action
-
6:44
how does jakafi® (ruxolitinib) work?
-
4:17
treatment sequencing and ongoing clinical trials in anemic myelofibrosis
-
1:16
the rationale for combining magrolimab with ruxolitinib in myelofibrosis
-
2:00
the development of anti-fibrotic agents for treating myelofibrosis
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
2:02
analyses from comfort trials of ruxolitinib for myelofibrosis
-
2:57
preliminary data from the manifest study: pelabresib in combination with ruxolitinib in mf
-
2:49
the 5-year update on the comfort-ii clinical trial of ruxolitinib
-
2:13
current and emerging treatment options for patients with mf who are ineligible for ruxolitinib
-
3:44
phase ii study update of navtemadlin in patients with myelofibrosis r/r to ruxolitinib
-
1:32
panobinostat plus ruxolitinib in myelofibrosis
-
1:15
reviewing the role and efficacy of ruxolitinib in myelofibrosis ten years after its approval
-
2:15
a phase i study investigating ruxolitinib and abemaciclib for primary or secondary myelofibrosis
-
2:41
bomedemstat combined with ruxolitinib for the treatment of mf: early results of a phase ii trial
-
8:03
phase ii trial of navitoclax and ruxolitinib in high-risk r/r myelofibrosis